China's Broncus H1 revenue nearly doubles on higher domestic equipment and consumable sales

Broncus Holding

27/08/2026 11:04

Overview
China interventional pulmonology device maker's interim revenue nearly doubled yr/yr
Company posted a wider net loss for the period
Revenue growth driven by commercialization of lung cancer and COPD treatment products

Outlook
Company did not provide specific financial guidance or financial forecasts in the interim report in the press release

Result Drivers
PRODUCT COMMERCIALIZATION - Co said revenue growth was driven by nationwide commercial promotion and adoption of BroncAblate for lung cancer and InterVapor for COPD
PRC CONSUMABLE DEMAND – Revenue growth was driven by higher PRC equipment and consumable sales, aided by marketing and therapeutic-consumable promotion
 
PRODUCT MIX SHIFT – Gross margin fell to 67.9% from 73.5% as product sales mix changed
MARKET EXPANSION - Co said approvals and registrations for BroncAblate, BroncTru and other products in Hong Kong, Thailand, Taiwan, Indonesia, Malaysia and Europe supported clinical adoption

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$3.30 mln
 
H1 Net Loss Attributable
 
$8.10 mln
 

Reuters Recommended Reads
Aug 27 - Jinhai Medical Technology H1 revenue jumps on China strength
Aug 24 - China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitions
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-27/1dd9e25f-6d44-4d80-926a-f81e7c91fc70.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)